https://doi.org/10.4081/ejtm.2023.10675

Anti-TPO antibody and thyroid hormone levels in Iranian female breast cancer patients and their association with prognostic factors: a case-control study

Vol. 33 No. 1 (2023)
Submitted: 13 June 2022
Accepted: 30 June 2022
Published: 16 March 2023
Breast neoplasms, anti-thyroid autoantibodies, thyroid hormones
Abstract Views: 785
PDF: 481
HTML: 19
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

Farahnaz Ghahremanfard
Cancer Research Center (CRC), Semnan University of Medical Sciences, Semnan, Iran, Islamic Republic of.
Elahe Jandaghi
dr.ejandaghi@semums.ac.ir
Department of Internal Medicine, Semnan University of Medical Sciences, Semnan, Iran; Department of Adult Rheumatology, School of Medicine, Loghman Hakim Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran, Islamic Republic of.
Rahimi Ghobad
Department of Internal Medicine, Kowsar Hospital, Semnan University of Medical Sciences, Semnan, Iran, Islamic Republic of.
Majid Mirmohammadkhani
Social Determinants of Health Research Center, Semnan University of Medical Sciences, Semnan, Iran, Islamic Republic of.
Mohamadamir Sarabi
Tehran Medical Sciences, Islamic Azad University, Tehran, Iran, Islamic Republic of.

The aim of this study was to assess prevalence of anti–thyroid peroxidase (anti-TPO) antibody and thyroid hormones in Iranian female breast cancer patients, compare them to a control population, and investigate their association with prognostic factors. In this case-control study, breast cancer patients were selected from a surgery clinic in a tertiary hospital and control group participants were enrolled from those who had visited for mammography screening. Participants with any history of thyroid disease, or thyroid related medication were excluded from both groups. Groups were assessed for levels of thyroid stimulating hormone (TSH), T3, T4, and anti-TPO. In addition, the status of estrogen receptors (ER), progesterone receptors (PR), and human epidermal growth factor receptor 2 (HER2) was determined for cancer patients. Overall 69 participants (39 cancer patients and 30 controls) were included. Difference in serum anti-TPO levels between the two groups was not statistically significant (p-value: 0.184). While a significant difference was observed for T4 and TSH levels between groups (p-value: 0.034 and <0.001, respectively), T3 levels did not reveal any significant difference (p-value: 0.177). In addition, ER, PR, and HER2 status were not correlated with anti-TPO levels. This results can serve as preliminary evidence that thyroid autoimmunity is not correlated with breast cancer incidence in Iranian female population. However, additional studies with larger sample sizes are required for more conclusive evidence

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.

Citations

Crossref
Scopus
Google Scholar
Europe PMC
Sancho-Garnier H, Colonna M. Épidémiologie des cancers du sein [Breast cancer epidemiology]. Presse Med. 2019 Oct;48(10):1076-1084. French. Epub 2019 Nov 6. DOI: https://doi.org/10.1016/j.lpm.2019.09.022
Nafissi N, Khayamzadeh M, Zeinali Z, Pazooki D, Hosseini M, Akbari ME. Epidemiology and histopathology of breast cancer in Iran versus other Middle Eastern countries. Middle East Journal of Cancer. 2018;9(3):243-51.
Kamińska M, Ciszewski T, Łopacka-Szatan K, Miotła P, Starosławska E. Breast cancer risk factors. Prz Menopauzalny. 2015 Sep;14(3):196-202. Epub 2015 Sep 30. DOI: https://doi.org/10.5114/pm.2015.54346
Ito K, Maruchi N. Breast cancer in patients with Hashimoto's thyroiditis. Lancet. 1975 Dec 6;2(7945):1119-21. DOI: https://doi.org/10.1016/S0140-6736(75)91006-5
Singh L, Lall B, Agarwall G. Thyroid in breast cancer. Asian Med J. 1982;25:157-63.
Weng CH, Chen YH, Lin CH, Luo X, Lin TH. Thyroid disorders and breast cancer risk in Asian population: a nationwide population-based case-control study in Taiwan. BMJ Open. 2018 Mar 30;8(3):e020194. DOI: https://doi.org/10.1136/bmjopen-2017-020194
Rasmusson B, Feldt-Rasmussen U, Hegedüs L, Perrild H, Bech K, Høier-Madsen M. Thyroid function in patients with breast cancer. Eur J Cancer Clin Oncol. 1987 May;23(5):553-6. DOI: https://doi.org/10.1016/0277-5379(87)90319-1
Kuijpens JL, Nyklíctek I, Louwman MW, Weetman TA, Pop VJ, Coebergh JW. Hypothyroidism might be related to breast cancer in post-menopausal women. Thyroid. 2005 Nov;15(11):1253-9. DOI: https://doi.org/10.1089/thy.2005.15.1253
Jiskra J, Barkmanova J, Limanova Z, Lánská V, Smutek D, Potlukova E, Antosova M. Thyroid autoimmunity occurs more frequently in women with breast cancer compared to women with colorectal cancer and controls but it has no impact on relapse-free and overall survival. Oncol Rep. 2007 Dec;18(6):1603-11. DOI: https://doi.org/10.3892/or.18.6.1603
Cristofanilli M, Yamamura Y, Kau SW, Bevers T, Strom S, Patangan M, Hsu L, Krishnamurthy S, Theriault RL, Hortobagyi GN. Thyroid hormone and breast carcinoma. Primary hypothyroidism is associated with a reduced incidence of primary breast carcinoma. Cancer. 2005 Mar 15;103(6):1122-8. DOI: https://doi.org/10.1002/cncr.20881
Søgaard M, Farkas DK, Ehrenstein V, Jørgensen JO, Dekkers OM, Sørensen HT. Hypothyroidism and hyperthyroidism and breast cancer risk: a nationwide cohort study. Eur J Endocrinol. 2016 Apr;174(4):409-14. DOI: https://doi.org/10.1530/EJE-15-0989
Maruchi N, Annegers JF, Kurland LT. Hashimoto's thyroiditis and breast cancer. Mayo Clin Proc. 1976 May;51(5):263-5.
Michalaki V, Kondi-Pafiti A, Gennatas S, Antoniou A, Primetis H, Gennatas C. Breast cancer in association with thyroid disorders. J BUON. 2009 Jul-Sep;14(3):425-8.
Wang B, Lu Z, Huang Y, Li R, Lin T. Does hypothyroidism increase the risk of breast cancer: evidence from a meta-analysis. BMC Cancer. 2020 Aug 6;20(1):733. PMID: 32762667; PMCID: PMC7409635. DOI: https://doi.org/10.1186/s12885-020-07230-4
Angelousi AG, Anagnostou VK, Stamatakos MK, Georgiopoulos GA, Kontzoglou KC. Mechanisms in endocrinology: primary HT and risk for breast cancer: a systematic review and meta-analysis. Eur J Endocrinol. 2012 Mar;166(3):373-81. Epub 2011 Oct 24. DOI: https://doi.org/10.1530/EJE-11-0838
Fang Y, Yao L, Sun J, Yang R, Chen Y, Tian J, Yang K, Tian L. Does thyroid dysfunction increase the risk of breast cancer? A systematic review and meta-analysis. J Endocrinol Invest. 2017 Oct;40(10):1035-1047. Epub 2017 May 17. PMID: 28516372. DOI: https://doi.org/10.1007/s40618-017-0679-x
Gogas J, Kouskos E, Tseleni-Balafouta S, Markopoulos C, Revenas K, Gogas G, Kostakis A. Autoimmune thyroid disease in women with breast carcinoma. Eur J Surg Oncol. 2001 Nov;27(7):626-30. PMID: 11669589. DOI: https://doi.org/10.1053/ejso.2001.1204
Giustarini E, Pinchera A, Fierabracci P, Roncella M, Fustaino L, Mammoli C, Giani C. Thyroid autoimmunity in patients with malignant and benign breast diseases before surgery. Eur J Endocrinol. 2006 May;154(5):645-9. DOI: https://doi.org/10.1530/eje.1.02108
Hardefeldt PJ, Eslick GD, Edirimanne S. Benign thyroid disease is associated with breast cancer: a meta-analysis. Breast Cancer Res Treat. 2012 Jun;133(3):1169-77. Epub 2012 Mar 21. DOI: https://doi.org/10.1007/s10549-012-2019-3
Fiore E, Giustarini E, Mammoli C, Fragomeni F, Campani D, Muller I, Pinchera A, Giani C. Favorable predictive value of thyroid autoimmunity in high aggressive breast cancer. J Endocrinol Invest. 2007 Oct;30(9):734-8. DOI: https://doi.org/10.1007/BF03350810
Muller I, Kilburn LS, Taylor PN, Barrett-Lee PJ, Bliss JM, Ellis P, Ludgate ME, Dayan CM. TPOAb and Thyroid Function Are Not Associated with Breast Cancer Outcome: Evidence from a Large-Scale Study Using Data from the Taxotere as Adjuvant Chemotherapy Trial (TACT, CRUK01/001). Eur Thyroid J. 2017 Jul;6(4):197-207. Epub 2017 Apr 4. DOI: https://doi.org/10.1159/000460246
Saraiva PP, Figueiredo NB, Padovani CR, Brentani MM, Nogueira CR. Profile of thyroid hormones in breast cancer patients. Braz J Med Biol Res. 2005 May;38(5):761-5. Epub 2005 May 25. DOI: https://doi.org/10.1590/S0100-879X2005000500014
Ortega-Olvera C, Ulloa-Aguirre A, Ángeles-Llerenas A, Mainero-Ratchelous FE, González-Acevedo CE, Hernández-Blanco ML, Ziv E, Avilés-Santa L, Pérez-Rodríguez E, Torres-Mejía G. Thyroid hormones and breast cancer association according to menopausal status and body mass index. Breast Cancer Res. 2018 Aug 9;20(1):94. DOI: https://doi.org/10.1186/s13058-018-1017-8
Ditsch N, Liebhardt S, Von Koch F, Lenhard M, Vogeser M, Spitzweg C, Gallwas J, Toth B. Thyroid function in breast cancer patients. Anticancer Res. 2010 May;30(5):1713-7.

How to Cite

Ghahremanfard, F., Jandaghi, E., Ghobad, R., Mirmohammadkhani, M., & Sarabi, M. (2023). Anti-TPO antibody and thyroid hormone levels in Iranian female breast cancer patients and their association with prognostic factors: a case-control study. European Journal of Translational Myology, 33(1). https://doi.org/10.4081/ejtm.2023.10675
Copyright (c) 2023 the Author(s) Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

PAGEPress has chosen to apply the Creative Commons Attribution NonCommercial 4.0 International License (CC BY-NC 4.0) to all manuscripts to be published.